Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INCEPTOR

Financiado

Investigate the mode of action ofInvestigate the mode of action of beta-carbolin...

Investigate the mode of action ofInvestigate the mode of action of beta-carboline derivative Harmine on increasing MHC-I expression and potentiating the Immune Checkpoint Blockade cancer imm One of the major mechanisms by which solid tumors escape anti-tumor immunity is the downregulation of major histocompatibility complex class I (MHC-I), which causes a failure in the recognition of tumor cells by the cytotoxicity T... ver más

31/03/2026

LIH

192K€

Presupuesto del proyecto: 192K€

Líder del proyecto

LUXEMBOURG INSTITUTE OF HEALTH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-20

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

LIH

191.76K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

RARITY RAtional design of canceR ImmunoTherapY one size does not f... 1M€ Cerrado

EXPAND IT EXPANDing Immune Cells and their Tumor Antigens during check... 3M€ Cerrado

RIPECROP RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming 3M€ Cerrado

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

Mel-Immune An integrative genetic approach for the exploration of melan... 3M€ Cerrado

Duración del proyecto: 35 meses Fecha Inicio: 2023-04-20
Fecha Fin: 2026-03-31

Líder del proyecto

LUXEMBOURG INSTITUTE OF HEALTH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 192K€

Descripción del proyecto One of the major mechanisms by which solid tumors escape anti-tumor immunity is the downregulation of major histocompatibility complex class I (MHC-I), which causes a failure in the recognition of tumor cells by the cytotoxicity T-cells. The project proposed by Dr. Teresa Ramos contains basic and translational aspects. The basic aspect relies on investigating the mechanisms of action of the ACB1801 molecule (harmine), reported by the host team to restore the MHC-I in tumor cells, using state-of-the-art technologies. The translational aspect of the project relies on providing the preclinical proof of concept for an innovative immunotherapy combination. The combination strategy consists of using a vaccination approach with Dendritic Cells (DC), pulsed with tumor cells pre-treated with ACB1801, in combination with immune checkpoint blockades. Although DC vaccination constitutes potent anticancer immunotherapy, clinical data showed that it does not provide robust benefits to patients. the innovative strategy of the project is based on simultaneous boosting the DC-based vaccine by ACB1801 and unleashing the power of T cells to induce a robust anti-tumor immune response which constitutes an unmet clinical need. The development of the present proposal will enable Dr. Ramos to achieve a broad range of new technologies and management skills through a variety of multidisciplinary training programs. This will represent a key step toward her final objective to become an independent and competitive scientist.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores